Dr Chengxue Helena Qin is the Laboratory Head and National Heart Foundation Future Fellow at Monash University and holds adjunct appointments at the Baker Heart and Diabetes Institute and the University of Melbourne. She is an emerging translational pharmacologist, with combined expertise in rational drug design, medicinal chemistry and pre-clinical models for cardiovascular diseases.

Dr Qin completed her B.BioMed. and PhD at Department of Pharmacology and Therapeutics and School of Chemistry at the University of Melbourne in 2010, before taking up a post-doctoral position at the Baker Heart and Diabetes Institute in 2011, and promoted to the Group Leader in 2017 and awarded with a 5-year Baker Fellowship in the same year. She has recently been recruited to Drug Discovery Biology Theme at Monash Institute of Pharmaceutical Science (Monash Parkville Campus) to establish her independent laboratory, focusing on developing effective and innovative treatments for cardiovascular disease.

Her current research focuses on formyl peptide receptors, a group of G-Protein-Coupled-Receptor involved in the regulation and resolution of inflammation. Dr Qin provided the first evidence that selectively engaging beneficial pathways at this receptor have significant therapeutic and translational potential against a range of cardiovascular disease. She has almost 40 publications including those in Nature Communications, Circulation, British Journal of Pharmacology, Journal of Medicinal Chemistry, Pharmacology and Therapeutics etc. She has attracted research funding from NHMRC, National Heart Foundation, Diabetes Australia Research Program, JDRF, CASS Foundation. Her achievements have also been recognized by numerous prestigious awards including National Heart Foundation Future Leader (2020-2023), JDRF Future Leader (2018-2019), Baker Fellow (2018-2022), Best Early Career Scientist at International Society for Heart Research (2017), Ralph Reader Prize (Basic Science, 2016), BPS/ASCEPT Outstanding Young Investigator Award (2015).